Clinical Trial Update: An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever. [Phase 3]

View source ↗

Summary

Phase 3 trial update for canakinumab in systemic juvenile idiopathic arthritis, including an open-label extension and treatment-naïve cohorts; study completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Systemic Juvenile Idiopathic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2017-03-10